RxDoctor Payments Data

Winston Burke

Podiatrist · Chicago, ILNPI 1619068038

Payments from drug & device makers

$2,159in general payments, 2019–2025

Across 74 payments — averaging $29.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$970
  • Smith+Nephew$645
  • Amgen$150
  • Paragon 28, Inc.$145
  • Stryker$108
  • Kerecis Limited$42
  • plus $99 from 5 others

What the payments were for

  • Food & beverage$2,159100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Organogenesis Inc.25$970
Smith+Nephew37$645
Amgen1$150
Paragon 28, Inc.1$145
Stryker(2 entities)3$108
Kerecis Limited2$42
Urgo Medical North America, LLC1$27
Acera Surgical, Inc.1$23
Next Science LLC1$19
Lightbody Medical Technologies Inc1$17
Tenex Health Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,159 in reported general payments places this provider in the 70th percentile of 409 podiatrist providers in Illinois.

See all podiatrist providers in Illinois

Medicare billing

Part B allowed, 2024
$5,172
Medicare patients
13
Services billed
60

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ammonium Lactate14$225
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$49

Paid to pharmacies, not to this prescriber.

Other podiatrist in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →